FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER WITH SELECT FGFR ALTERATIONS

被引：0
|
作者：
Vilaseca, Antoni
Jayram, Gautam
Raventos, Carles
Shore, Neal D.
Zainfeld, Daniel
Kang, Taek Won
Ku, Ja Hyeon
Meeks, Joshua
Rodriguez Faba, Oscar
Roghmann, Florian
Daneshmand, Siamak
Beeharry, Neil
Cost, Carrye R.
Kalota, Anna
Lauring, Josh
Peterson, Michelle R.
Quiroz, Michelle
Stone, Nicole L.
Zhu, Wei
Gurrero Ramos, Felix
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD48-02
引用
收藏
页码：E987 / E988
页数：2
相关论文
共 50 条
  • [1] First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations
    Vilaseca, A.
    Jayram, G.
    Raventos, C.
    Shore, N. D.
    Zainfeld, D.
    Kang, T. W.
    Ku, J. H.
    Meeks, J.
    Rodriguez Faba, O.
    Roghmann, F.
    Daneshmand, S.
    Beeharry, N.
    Cost, C. R.
    Kalota, A.
    Lauring, J.
    Peterson, M. R.
    Quiroz, M. Q.
    Stone, N. L.
    Zhu, W.
    Gurrero-Ramos, F.
    EUROPEAN UROLOGY, 2024, 85 : S1506 - S1507
  • [2] First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non emuscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
    Vilaseca, A.
    Jayram, G.
    Raventos, C.
    Shore, N. D.
    Zainfeld, D.
    Kang, T. W.
    Ku, J. H.
    Meeks, J.
    Faba, O. Rodriguez
    Roghmann, F.
    Daneshmand, S.
    Beeharry, N.
    Cost, C.
    Kalota, A.
    Lauring, J.
    Peterson, M.
    Quiroz, M.
    Stone, N.
    Zhu, W.
    Guerrero-Ramos, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1343 - S1343
  • [3] Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-inhuman study.
    Vilaseca, Antoni
    Guerrero, Felix
    Zainfeld, Daniel
    Shore, Neal D.
    Rodriguez Faba, Oscar
    Meijer, Richard P.
    Alfred Witjes, Alfred
    Jackson McRee, Autumn
    Kalota, Anna
    Stone, Nicole L.
    David Lauring, Josh
    Zhu, Wei
    Beeharry, Neil
    O'Dondi, Lang A.
    Jayram, Gautam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFRALTERED INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
    Roger, Li
    Gautam, Jayram
    Angela, Girvin
    Anne, O'Hagan
    Sabine, D. Brookman-May
    Jiao, Song
    Nicole, Stone
    Cateau, Van Oevelen
    Jose, M. Calderon
    Lauren, Crow
    Neil, Beeharry
    Spyros, Triantos
    Benjamin, Pradere
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [5] Safety and pharmacokinetics (PK) of TAR-210 in Japanese with bladder cancer and select FGFR alterations: phase 1 study
    Nishimura, K.
    Kimura, T.
    Kikuchi, E.
    Kitamura, H.
    Hashibe, S.
    Mukai, M.
    Fujikawa, E.
    Ote, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1386 - S1386
  • [6] Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
    Eisner, Joel R.
    de Jong, Florus C.
    Shibata, Yoichiro
    Mayhew, Gregory M.
    Davison, James M.
    Carcione, Jenna
    Pappan, Kirk L.
    Thomas, Shibu
    Triantos, Spyros
    Santiago-Walker, Ademi
    Baig, Mahadi
    Milburn, Michael V.
    Beebe, Kirk D.
    Zuiverloon, Tahlita C. M.
    CLINICAL CANCER RESEARCH, 2024, 30 (23) : 5374 - 5384
  • [7] Efficacy and safety of valrubicin in non-muscle-invasive bladder cancer in older and younger patients
    Cookson, Michael S.
    Lihou, Christine Francis
    Harper, Samira Q.
    Li, Thomas
    Chitra, Surya
    Tutrone, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] The Efficacy and Safety of Hyperthermia Intravesical Chemotherapy in the Treatment of Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis
    Duan, Huanglin
    Deng, Zanxuan
    Zou, Junrong
    Zhang, Guoxi
    Zou, Xiaofeng
    Xie, Tianpeng
    UROLOGIA INTERNATIONALIS, 2024, 108 (04) : 322 - 333
  • [9] Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer
    Domingos-Pereira, Sonia
    Cesson, Valerie
    Chevalier, Mathieu F.
    Derre, Laurent
    Jichlinski, Patrice
    Nardelli-Haefliger, Denise
    ONCOIMMUNOLOGY, 2017, 6 (01):
  • [10] Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer
    Hendricksen, Kees
    Witjes, Wim P. J.
    Idema, Jan G.
    Kums, Jan J. M.
    Trip, Oncko B. van Vierssen
    de Bruin, Marcel J. F. M.
    Vergunst, Henk
    Caris, Christien T. M.
    Janzing-Pastors, Maria H. D.
    Witjes, J. Alfred
    EUROPEAN UROLOGY, 2008, 53 (05) : 984 - 991
12345